Elbasvir/Grazoprevir Experience- A New Glance at HCV Treatment: Case Report
Author(s) -
Mustafa Kemal Çelen,
I. Akdemir,
Recep Tekin,
Kadım Bayan,
Celal Ayaz
Publication year - 2017
Publication title -
viral hepatitis journal
Language(s) - English
Resource type - Journals
eISSN - 2147-2939
pISSN - 1307-9441
DOI - 10.4274/vhd.10337
Subject(s) - medicine
Hepatitis C is a viral disease having a worldwide importance and posing a risk for liver complications. With the new treatment options, it is easy to manage with higher rates of success. Among them, one of the most recent one is elbasvir/grazoprevir option. This study presents the results of two treatment-naive patients treated with elbasvir/grazoprevir. The first case was a male non-cirrhotic patient and the second one was a female who suffered from compensated hepatic cirrhosis. Both patients received elbasvir/grazoprevir 50/100 mg in a single tablet for 12 weeks. Persistent viral response was achieved in both patients and no side effect was observed during the treatment. Elbasvir/grazoprevir combination, one of the recent treatments, was considered effective and tolerable
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom